Head-To-Head Comparison: United Therapeutics Corporation (UTHR) vs. Its Competitors
United Therapeutics Corporation (NASDAQ: UTHR) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare United Therapeutics Corporation to related companies based on the strength of its dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
Valuation and Earnings
This table compares United Therapeutics Corporation and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|United Therapeutics Corporation||$1.63 billion||$1.01 billion||13.67|
|United Therapeutics Corporation Competitors||$207.80 million||-$2.19 million||-0.33|
United Therapeutics Corporation has higher revenue and earnings than its competitors. United Therapeutics Corporation is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
47.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.8% of United Therapeutics Corporation shares are held by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for United Therapeutics Corporation and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|United Therapeutics Corporation||3||6||2||0||1.91|
|United Therapeutics Corporation Competitors||790||2961||6462||145||2.58|
United Therapeutics Corporation currently has a consensus target price of $134.70, indicating a potential upside of 14.94%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 5.06%. Given United Therapeutics Corporation’s higher possible upside, research analysts plainly believe United Therapeutics Corporation is more favorable than its competitors.
Volatility & Risk
United Therapeutics Corporation has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, United Therapeutics Corporation’s competitors have a beta of 1.67, indicating that their average stock price is 67% more volatile than the S&P 500.
This table compares United Therapeutics Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|United Therapeutics Corporation||24.18%||20.96%||16.03%|
|United Therapeutics Corporation Competitors||-11,838.95%||-413.63%||-47.78%|
United Therapeutics Corporation beats its competitors on 7 of the 13 factors compared.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.